Results 201 to 210 of about 3,222 (233)
Some of the next articles are maybe not open access.

[Antiaggregant activity of hypoglycemic drugs].

Eksperimental'naia i klinicheskaia farmakologiia, 2010
We have compared the inhibitory effects of a series of hypoglycemic drugs, including glyclazide, glibenclamide, glucophage, rosiglitazone, diabenol (a new antidiabetic drug), and acetylsalicylic acid (reference antiaggregant preparation), on rabbit platelet aggregation in vitro induced by adding 5 mM ADP solution.
A A, Spasov   +2 more
openaire   +1 more source

Platelet Antiaggregants in Pregnancy

Revista Española de Cardiología (English Edition), 2009
Pablo Santiago-Díaz   +3 more
openaire   +1 more source

Potential Drug-Drug Interactions in Adults Receiving Oral Anticoagulant and Antiaggregant Therapy

Expert Opinion on Drug Safety, 2023
Nazife Gökçe Akpınar, Sema Ketenci
exaly  

[Platelet antiaggregants and coronary pathology].

La Revue du praticien, 1990
Platelet inhibitors have widely been studied in various clinical situations resulting from atherosclerosis of the coronary arteries. At present, aspirin is virtually the only drug that has proved to be effective in all cases where the risk of coronary thrombosis was very high. Administered in daily doses of 160 to 1,500 mg, acetylsalicylic acid reduces
A, Castaigne   +2 more
openaire   +1 more source

Synthesis and Antiaggregant and Anticoagulant Activity of New 1-(4-Alkyloxybenzyl)-1H-Azoles and 1-(Adamantyl-1)-2-[4-(1H-Azol-1-Ylmethyl)-Phenoxy]Ethanones

Pharmaceutical Chemistry Journal, 2021
Alexander A Golovanov   +2 more
exaly  

[Anticoagulation and antiaggregation during pregnancy].

Therapeutische Umschau. Revue therapeutique, 2003
For haemostatic and circulatory reasons pregnancy is associated with an about 6-fold relative increase of thrombotic risk which is further raised by additional risk factors, such as history of thrombosis or acquired and hereditary thrombophilia, respectively.
F Demarmels, Biasiutti   +1 more
openaire   +1 more source

[Anticoagulation and antiaggregation in cardiac patients].

Therapeutische Umschau. Revue therapeutique, 2003
Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1.5%. Both aspirin and clopidogrel reduce the rate of cardiovascular events in patients with coronary disease. Clopidogrel in addition to aspirin further reduces cardiovascular events, but is associated with and increased bleeding risk. Recent studies in
openaire   +1 more source

Home - About - Disclaimer - Privacy